Charlie Mamrak has joined Chicago-based private equity firm Linden LLC as an operating partner. He previously was CEO of PML Microbiologicals.
Linden LLC, a Chicago-based private equity firm that focuses on middle market leveraged buyout investments in the healthcare and life science sector, today announced that it has further enhanced its operating talent with the addition of Charlie Mamrak as an Operating Partner.
Mr. Mamrak brings over 20 years of life science and laboratory experience to Linden. Prior to joining Linden, Charlie was CEO of PML Microbiologicals, where he and his team grew revenues 90% in under three years. He then engineered a highly profitable divestiture for their private equity investors to a strategic buyer. Prior to PML, Charlie was CEO for a private equity backed contract packaging and manufacturing business focused on solid dose pharmaceuticals. Before his private equity experience, Charlie held several general management posts at Fisher Scientific, leading both the Acros Organics North American and Global Custom Chemistry businesses. Charlie also held senior positions with Sigma-Aldrich where he helped develop and launch their line of Discovery HPLC columns. Earlier in his career, Charlie worked in and managed several contract research laboratories including DuPont, CH2M Hill and Corning Laboratories. Charlie studied Biomedical Engineering at Pennsylvania State University and holds a Bachelors degree in Biology and Chemistry from Moravian College.
Mr. Mamrak augments Linden’s prestigious group of Operating Partners who collectively have over a century of healthcare experience. Together with Operating Partner Mr. Fran Lunger, former CEO of Millipore, Charlie will work closely with Linden’s investment team to research and identify new opportunities in life science as well as supporting portfolio companies. Linden anticipates that Charlie will serve as a Board Member and operating executive of at least one platform company.
About Linden LLC
Linden is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden’s strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden’s portfolio includes BarrierSafe Solutions International, Behavioral Centers of America, Corpak MedSystems, Drayer Physical Therapy Institute, Focused Health Solutions, Ranir, and Suture Express. For additional information, please visit www.lindenllc.com.